2 results
Approved WMORecruiting
To determine if the addition of midostaurin to daunorubicin/ cytarabine induction, high dose cytarabine consolidation, and continuation therapy improves overall survival (OS) in both the mutant FLT3-ITD and FLT-3 TKD AML patients.
Approved WMOPending
The primary efficacy objective for this study is to demonstrate non-inferiority of ocrelizumab compared with fingolimod